Edwards Lifesciences (EW) Tops Q2 EPS by 20c; Raises Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Edwards Lifesciences Reports Second Quarter Results
July 26, 2017 4:15 PM EDTIRVINE, Calif., July 26, 2017 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today reported financial results for the quarter ended June 30, 2017.Â
Second Quarter and Recent Highlights:
Sales grew 11 percent to $842 million; underlying1 sales increased 15 percent to $864 million Global THVT sales grew 16 percent to $488 million; underlying sales increased 23 percent U.S. THVT sales grew 28 percent to $316 million EPS was $0.86, an increase of 48 percent; adjusted2... More